
immatics’ investigational cancer vaccine has increased survival rates in patients with renal cell carcinoma. In a late-stage trial, the German …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

